SCHEMBL8964683

SCHEMBL8964683

C=CCc1ccc(C)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
PPARG P37231 2/20 0.47
PPARD Q03181 2/20 0.47
PPARA Q07869 1/20 0.47
XDH P47989 1/20 0.47
MAPT P10636 6/20 0.46
GABRA1 P14867 4/20 0.46
GABRB2 P47870 4/20 0.46
GAA P10253 4/20 0.46
NPSR1 Q6W5P4 3/20 0.46
MEN1 O00255 3/20 0.46
CNR2 P34972 3/20 0.46
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 2/20 0.46
CNR1 P21554 2/20 0.46
ALDH2 P05091 1/20 0.46
AKR1B1 P15121 1/20 0.46
HPGD P15428 1/20 0.46
CYP3A4 P08684 4/20 0.43
ALOX5 P09917 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7044076 0.82 ALDH1A1 (0.44) ALDH1A1MAPTGAANPSR1MEN1
SCHEMBL1733361 0.81 XDH (0.52) ALDH1A1PPARGPPARDPPARAXDH
SCHEMBL11043517 0.81 IDO1 (0.52) ALDH1A1PPARGPPARDPPARAXDH
SCHEMBL30271269 0.81 IDO1 (0.52) ALDH1A1PPARGPPARDPPARAXDH
SCHEMBL1734236 0.81 XDH (0.52) ALDH1A1PPARGPPARDPPARAXDH
SCHEMBL9003492 0.78 GABRA1 (0.49) ALDH1A1PPARGPPARDPPARAXDH
SCHEMBL1755263 0.77 NPSR1 (0.41) ALDH1A1MAPTGAANPSR1MEN1
SCHEMBL3763570 0.77 CYP3A4 (0.46) ALDH1A1MAPTGAANPSR1MEN1
SCHEMBL12107538 0.76 CYP3A4 (0.54) ALDH1A1MAPTGAANPSR1KDM4E
SCHEMBL11835071 0.76 CYP3A4 (0.61) ALDH1A1PPARGPPARDPPARAXDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
EP-1569919-B1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2012-04-18 EP disclosed
US-7642277-B2 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-05 US disclosed
EP-0410379-B1 Pharmaceutically active 3-aryl and 3-heteroaryl-2-fluoro-1-olefins MERRELL DOW PHARMA (US) 1996-01-31 EP disclosed
US-5068465-A Hypotensive agents or enzyme inhibitors for treatment of hypertension MERRELL DOW PHARMACEUTICALS INC. (US) 1991-11-26 US disclosed
EP-0410379-A2 Pharmaceutically active 3-aryl and 3-heteroaryl-2-fluoro-1-olefins MERRELL DOW PHARMACEUTICALS INC. (US) 1991-01-30 EP disclosed
US-4981868-A ENZYME INHIBITORS, HYPOTENSIVES MERRELL DOW PHARMACEUTICAL (US) 1991-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 ALDH1A1 3113/4885PPARG 2825/4885PPARD 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.